The Aduhelm controversy has not yet ended the Bojian Tecfidera generic drug patent case has fallen again

CompilationTom Lee

Despite Bojian’s best efforts, Tecfidera generic drugs seem to continue to be sold on the market

According to court documents filed on Tuesday, the U.

This case originated from a long-standing patent dispute between Bojian and Viatris, whose predecessor was Mylan

At that time, Bojian filed an appeal

According to Tuesday’s ruling, Bo Jianfang can still apply for a retrial and may appeal to the Supreme Court

Abrahams added that due to the bad news from Tecfidera and Bojian’s struggling in several other business areas, the company’s stock price may be “close to the bottom”

However, the fact is that the drug has continued to face safety disputes and payment barriers after it was approved by the US FDA

However, the company did not completely give up its efforts in the multiple sclerosis market.

Reference source: Biogen takes another blow as appeal for Tecfidera patent revival falls short